One of the concerns and arguments we've heard is that even if we make CAMR work more effectively, at the end of the day, developing countries want to buy their drugs and medications as cost-effectively as they can. It sounds as if that's what's happening now. The main source is India. I know that we've touched on this already, and Mr. McTeague asked this question as well, but just help us understand that a little further. If at the end of the day, India, China, or even the U.S. provide less expensive generic medications than Canada does, how can we compete or be involved in this process?
On October 21st, 2010. See this statement in context.